is reading and analyzing
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$RBII the best ones take some patience.
$RBII Loving this level, adding some more
$RBII outpatient clinics can drive 5 million in annual revs.
$RBII Stock is up on decent opening volume.
Globally, the anxiety and depression treatment market has been valued at over $15 billion. $RBII
Anxiety disorders are the most commonly diagnosed mental health illness in the USA today, affecting more than 40 million adults.
$RBII Growing numbers of clinical studies suggest that there is untapped potential in CBD as a treatment for a broad range of ailments from chronic anxiety to substance abuse disorder.
CBD only variant of Cannophen Capsules and Vape Cartridges has entered into an initial production run. $RBII
Buckle up it is Power Hour. $RBII
Ohio is within the top ten states for overdose opiod deaths. Very sad, but very glad to see how $RBII is bringing real solutions to the table. $RBII
CBD only Cannophen will open up a $5Billion global market for $RBII
$RBII I think we can expect this to be a perfect entry.
$RBII think we should have some more big news coming soon.
$RBII sounds like more solid developments around the corner here.
CBD only variant is primed for the $5Billion CBD market! $RBII
$RBII outpatient clinics can drive 5 million in annual revs.
Initial results seem to indicate that CBD could change the face of opioid addiction treatment, succeeding where other conventional therapies have had mixed results.
Perhaps most promising, however, are the results from recent studies indicating that CBD may be a highly effective treatment for opioid use disorder.
Globally, the anxiety and depression treatment market has been valued at over $15 billion.
$RBII Anxiety disorders are the most commonly diagnosed mental health illness in the USA today, affecting more than 40 million adults.
Growing numbers of clinical studies suggest that there is untapped potential in CBD as a treatment for a broad range of ailments from chronic anxiety to substance abuse disorder.
CBD only variant of Cannophen Capsules and Vape Cartridges has entered into an initial production run.
$RBII closed up 7.69 percent on Friday, July 19, 2019, on 25 percent of normal volume.
$RBII This looks great. Tight spread. Volume is growing. Great long play.
$RBII just recently purchased a 40,000 square foot former recreation facility that will be renovated for use as a behavioral health inpatient center. Their purpose of treating all types of substance abuse
$RBII is committed to fighting the opioid epidemic. Its the largest illicit drug epidemic to hit us in USA history.
Sandusky Treatment facility will drive some major revenues. $RBII
$RBII Cannophen CBD only should open up a global market for $RBII, especially if they take an online distribution approach.
$RBII sounds like more solid developments around the corner here.
$RBII awareness coming to a tipping point.
$RBII At the Rising Biosciences offices, we have been buzzing like a beehive in recent days working on new developments.
$RBII We are highly gratified to announce that CBD only Cannophen will be coming to the market soon, both for what it will mean for our shareholders and for how it will advance our purpose in combating the opioid crisis in the Midwest and beyond.
$RBII Our debut run back in June tested at a full 25mg CBD per capsule, so we anticipate similar results for this batch of our CBD only variant.
The first production run is done and initial samples are being sent to the lab for testing.
The Company can broaden its distribution footprint with fewer regulatory pit-stops along the way to reaching the deepest possible target market.
CBD-only Cannophen is less encumbered by strict guidelines governing the distribution of products which contain THC.
$RBII ran into resistance at its 50 day moving average.
Looking for a bounce after $RBII closed down 3.7 percent on Thursday, July 18, 2019, on 6 percent of normal volume.
$RBII what an undiscovered gem.
Adding more today $RBII still building up the full head of steam.